PL189756B1 - Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych - Google Patents

Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych

Info

Publication number
PL189756B1
PL189756B1 PL97332960A PL33296097A PL189756B1 PL 189756 B1 PL189756 B1 PL 189756B1 PL 97332960 A PL97332960 A PL 97332960A PL 33296097 A PL33296097 A PL 33296097A PL 189756 B1 PL189756 B1 PL 189756B1
Authority
PL
Poland
Prior art keywords
seq
leu
ala
arg
gly
Prior art date
Application number
PL97332960A
Other languages
English (en)
Polish (pl)
Other versions
PL332960A1 (en
Inventor
Charles A. Mcwherter
Yiqing Feng
Neena Summers
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of PL332960A1 publication Critical patent/PL332960A1/xx
Publication of PL189756B1 publication Critical patent/PL189756B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL97332960A 1996-10-25 1997-10-23 Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych PL189756B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3404496P 1996-10-25 1996-10-25
PCT/US1997/018703 WO1998018926A1 (en) 1996-10-25 1997-10-23 Circularly permuted erythropoietin receptor agonists

Publications (2)

Publication Number Publication Date
PL332960A1 PL332960A1 (en) 1999-10-25
PL189756B1 true PL189756B1 (pl) 2005-09-30

Family

ID=21873960

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97332960A PL189756B1 (pl) 1996-10-25 1997-10-23 Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych

Country Status (13)

Country Link
US (1) US20060172932A1 (https=)
EP (1) EP0939816A1 (https=)
JP (1) JP2001503266A (https=)
KR (1) KR20000052807A (https=)
CN (1) CN1234073A (https=)
AU (1) AU721196B2 (https=)
BR (1) BR9712675A (https=)
CA (1) CA2268001A1 (https=)
CZ (1) CZ130199A3 (https=)
NO (1) NO991906L (https=)
NZ (1) NZ334546A (https=)
PL (1) PL189756B1 (https=)
WO (1) WO1998018926A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
CN100383238C (zh) 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
JP2008527980A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US20080260746A1 (en) * 2005-11-24 2008-10-23 Laboratoires Serono Sa Erythropoietin Polypeptides and Uses Thereof
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ, インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するactriibタンパク質およびその改変体およびその使用
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
RS61391B1 (sr) 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用
CN110144010B9 (zh) 2018-02-14 2021-01-05 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
CA2069746A1 (en) * 1990-09-28 1992-03-29 Jonathan I. Rosen Hybrid growth factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands

Also Published As

Publication number Publication date
PL332960A1 (en) 1999-10-25
NO991906D0 (no) 1999-04-21
AU5081098A (en) 1998-05-22
NZ334546A (en) 2000-12-22
JP2001503266A (ja) 2001-03-13
NO991906L (no) 1999-04-21
US20060172932A1 (en) 2006-08-03
CZ130199A3 (cs) 1999-07-14
AU721196B2 (en) 2000-06-29
BR9712675A (pt) 1999-10-19
KR20000052807A (ko) 2000-08-25
EP0939816A1 (en) 1999-09-08
WO1998018926A1 (en) 1998-05-07
CA2268001A1 (en) 1998-05-07
CN1234073A (zh) 1999-11-03

Similar Documents

Publication Publication Date Title
PL189756B1 (pl) Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych
JP4949844B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
KR100459984B1 (ko) 에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드
AU734594B2 (en) Circularly permuted polypeptides as novel stem cell factor receptor agonists
JP4266028B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
MX2012006397A (es) PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
JP2013173763A (ja) エリスロポエチンレセプターペプチドの処方および使用
US6660257B1 (en) Circular permuteins of flt3 ligand
JP2008519858A (ja) エリスロポエチンレセプターに結合する新規ペプチド
JP3292873B2 (ja) 組換肝実質細胞増殖因子
JP3318323B2 (ja) 組換肝実質細胞増殖因子
MXPA99003874A (es) Agonistas del receptor de eritropoyetina circularmente permutados
JPH1070990A (ja) 組換肝実質細胞増殖因子
HK1088906B (en) Peptides that bind to the erythropoietin receptor
HK1088616B (en) Novel peptides that bind to the erythropoietin receptor

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20051023